title: Path to approval proves rocky for copycat biodrugs.
authors.forename: Meredith
authors.initials: M
authors.lastname: Wadman
mesh_terms: D001709:Biotechnology / Q000191:economics / Q000331:legislation & jurisprudence; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D016568:Drugs, Generic / Q000009:adverse effects / Q000191:economics*; D005062:European Union; D019382:Human Growth Hormone / Q000191:economics; D006801:Humans; D016898:Interferon-alpha / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D016568:Drugs, Generic; D016898:Interferon-alpha; D019382:Human Growth Hormone